Lactobacillus salivarius UCC118™ Dampens Inflammation and Promotes Microbiota Recovery to Provide Therapeutic Benefit in a DSS-Induced Colitis Model

Namrata Iyer; Michelle A Williams; Amy A O'Callaghan; Elaine Dempsey; Raul Cabrera-Rubio; Mathilde Raverdeau; Fiona Crispie; Paul D Cotter; Sinéad C Corr

doi:10.3390/microorganisms10071383

Lactobacillus salivarius UCC118™ Dampens Inflammation and Promotes Microbiota Recovery to Provide Therapeutic Benefit in a DSS-Induced Colitis Model

Microorganisms. 2022 Jul 9;10(7):1383. doi: 10.3390/microorganisms10071383.

Authors

Namrata Iyer^{1

2}, Michelle A Williams¹, Amy A O'Callaghan¹, Elaine Dempsey^{1

3}, Raul Cabrera-Rubio^{2

4}, Mathilde Raverdeau³, Fiona Crispie^{2

4}, Paul D Cotter^{2

4}, Sinéad C Corr^{1

2}

Affiliations

¹ School of Genetics and Microbiology, Moyne Institute for Preventative Medicine, Trinity College Dublin, D02 R590 Dublin, Ireland.
² APC Microbiome Ireland, Co., T12 K8AF Cork, Ireland.
³ School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, D02 R590 Dublin, Ireland.
⁴ Teagasc Food Research Centre, Moorepark, P61 C996 Cork, Ireland.

Abstract

The use of probiotics such as Lactobacillus and Bifidobacterium spp. as a therapeutic against inflammatory bowel disease (IBD) is of significant interest. Lactobacillus salivarus strain UCC118^TM is a commensal that has been shown to possess probiotic properties in vitro and anti-infective properties in vivo. However, the usefulness of UCC118 ^TM as a therapeutic against colitis remains unclear. This study investigates the probiotic potential of Lactobacillus salivarius, UCC118™ in a mouse model of colitis. DSS-induced colitis was coupled with pre-treatment or post-treatment with UCC118^TM by daily oral gavage. In the pre-treatment model of colitis, UCC118^TM reduced the severity of the disease in the early stages. Improvement in disease severity was coupled with an upregulation of tissue IL-10 levels and increased expression of macrophage M2 markers. This anti-inflammatory activity of UCC118^TM was further confirmed in vitro, using a model of LPS-treated bone marrow-derived macrophages. Taken together, these results suggest that UCC118^TM may promote the resolution of inflammation. This was supported in a mouse model of established DSS-induced colitis whereby UCC118^TM treatment accelerated recovery, as evidenced by weight, stool, histological markers and the recovery of microbiome-associated dysbiosis with an increased abundance of beneficial commensal species. These results demonstrate the potential of Lactobacillus salivarius UCC118^TM as a probiotic-based therapeutic strategy to promote health through the upregulation of anti-inflammatory IL-10 and protect against dysbiosis during IBD.

Keywords: colitis; inflammation; microbiota; probiotic.

Abstract

Grants and funding